Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Alnylam Pharma (ALNY) Tops Q4 EPS by 24c
February 6, 2020 8:08 AM ESTAlnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.98), $0.24 better than the analyst estimate of ($2.22). Revenue for the quarter came in at $71.68 million versus the consensus estimate of $71.92 million.
Achieved Fourth Quarter and Full Year 2019 ONPATTRO® (patisiran) Global Net Product Revenues of $55.8 Million and $166.4 Million, RespectivelyAs of Year-End 2019, Over 750 Patients Worldwide Receiving Commercial ONPATTRO, with Over 1,000 Total Patients Worldwide Being Treated with PatisiranObserved Strong Initial Demand for GIVLAARI (givosiran) in the U.S., with 13 Start Forms Received in First Six Weeks after FDA ApprovalReported Third Positive 2019 Phase 3 Result with... More